| Dag Aarsland | UK | DLB UPDATE OR RESILIENCE FACTORS IN AD |
| Roy N Alcalay | Israel | GBA-1 FOCUSED TRIALS IN PARKINSON'S |
| Maria Ankarcrona | Sweden | IN VIVO MODULATION OF MICROGLIAL MITOCHONDRIA-ER CONTACTS ALLEVIATES BRAIN INFLAMMATION IN AD MICE. |
| Johannes Attems | UK | NEUROPATHOLOGY |
| Rhoda Au | USA | DIGITAL IS THE LIFEBLOOD OF AI SOLUTIONS FOR AD/PD |
| Tim Bartels | UK | THE PERIPHERY IN THE PATHOMECHANISM OF SYNUCLEINOPATHIES |
| Mathew Blurton Jones | USA | A NOVEL GENE THERAPY APPROACH TO TARGET MICROGLIA IN VIVO |
| Bradley Boeve | USA | CLINICAL TRIAL DESIGN CONSIDERATIONS FOR DISEASE-MODIFYING TRIALS IN REM SLEEP BEHAVIOR DISORDER |
| Guojun Bu | Hong-Kong PRC | APOE-DEPENDENT LIPID DYSREGULATION IN ALZHEIMER’S DISEASE |
| Luc Buee | France | THE PROMISE OF INTRABODIES IN NEURODEGENERATION |
| Ornit Chiba-Falek | USA | TRANSFORMING ALZHEIMER'S DISEASE DRUG DISCOVERY THROUGH SINGLE-CELL MULTI-OMICS |
| Claudio A. Cuello | Canada | PROGRESS ON MICRO-LITHIUM THERAPY IN ALZHEIMER'S |
| Jeffrey Cummings | USA | TRENDS IN DRUG DEVELOPMENT FOR ALZHEIMER'S DISEASE |
| Bart De Strooper | Belgium | THE ROLE OF ANTIGEN PRESENTATION BY MICROGLIA IN ALZHEIMER’S DISEASE |
| Daniel Ferreira Padilla | Sweden | BIOMARKERS IN MANIFEST AND PRODROMAL DEMENTIA WITH LEWY BODIES |
| Dan Frenkel | Israel | FROM AGE-RELATED METABOLIC DYSFUNCTION TO ALZHEIMER'S DISEASE: IDENTIFYING NOVEL THERAPEUTIC TARGET |
| Giovanni Frisoni | Switzerland | THE LANCET COMMISSION ON CLINICAL PATHWAYS FOR ALZHEIMER'S DISEASE AND RELATED DISORDERS: MISSION, VISION, AND OBJECTIVES |
| Lutz Froelich | Germany | FROM EMA TO G-BA – A CRITIQUE ON THE GERMAN HTA SYSTEM EVALUATING THE ADDED BENEFIT OF AMYLOID TARGETING THERAPY IN GERMANY |
| Angela Genge | Canada | NEWEST RESULTS ON ALS DRUG DEVELOPMENT |
| Klaus Gerwert | Germany | BLOOD-BASED- BIOMARKER FOR PRECLINICAL AND CLINICAL PARKINSON`S |
| Lea Grinberg | USA | LEVERAGING DISEASE SPECIFIC SLEEP AND CIRCADIAN DEGENERATION PATTERNS AS EARLY BIOMARKERS OF NEURODEGENERATION |
| Christian Haass | Germany | EFFECTS OF MICROGLIAL DYSFUNCTION ON MICROVESSELS |
| Oskar Hansson | Sweden | DIAGNOSTICS OF NEURODEGENERATIVE DISEASES |
| Elizabeth Head | USA | TAU PATHOLOGY IN DOWN SYNDROME AND ASSOCIATION WITH AGE |
| Michael Heneka | Luxemborg | TYPE-1 INTERFERON RESPONSE IN NEURODEGENERATIVE DISEASE: DRIVING FACTOR OR BYSTANDER REACTION? |
| Makato Higuchi | Japan | MOLECULAR IMAGING OF TAU AND Α-SYNUCLEIN PATHOLOGIES: FROM CROSS-SECTIONAL MAPPING TO LONGITUDINAL TRACKING |
| Henne Holstege | The Netherlands | HOW THE GENETIC ARCHITECTURE IN COGNITIVELY HEALTHY CENTENARIANS EXPLAINS THEIR LOW NEUROPATHOLOGY BUILD-UP |
| David Holtzman | USA | EFFECTS OF APOE PROTECTIVE VARIANTS ON AD-RELATED PATHOLOGIES |
| Ole Isacson | USA | AGING, APOE AND GBA1 DETERMINE HIPPOCAMPAL GENE RESPONSES TO LIPID DYSHOMEOSTASIS IN PD, LBD AND AD IN VIVO MODELS |
| Takeshi Iwatsubo | Japan | BIOMARKER AND PET IN THE LONGITUDINAL COHORT AND REGISTRY STUDIES FOR PRECLINICAL AND PRODROMAL AD IN JAPAN |
| Miia Kivipelto | Sweden | AD-RIDDLE - REAL WORLD IMPLEMENTATION AND VALIDATION OF EARLY DETECTION TOOLS AND TAILORED INTERVENTIONS |
| Frank Laferla | USA | MODEL-AD: NEW INSIGHTS & ADVANCES |
| Virginia Lee | USA | TRANSMISSION OF TAU AND A-SYNUCLEIN STRAINS IN NEURODEGENERATION |
| Cynthia Lemere | USA | COMBINATION TREATMENTS TO MITIGATE ARIA |
| Frank Longo | USA | TBA |
| Ken Marek | USA | UNDERSTANGING BIOLOGY OF NEURONAL SYNUCLEIN DISEASE IN THE PPMI |
| Pamela McLean | USA | COPATHOLOGY IN LEWY BODY DEMENTIA |
| Michelle Mielke | USA | OUTCOMES OF A CLINICAL CARE PATHWAY FOR EARLY DIAGNOSIS AND USE OF BIOMARKERS IN A LARGE HEALTH SYSTEM |
| Marc Mintun | USA | UPDATE ON STRATEGIES TO PREVENT THE SYMPTOMS OF ALZHEIMER'S DISEASE |
| John Morris | USA | EVAULATING EFFICACY OF AMYLOID TARGETING TREATMENT IN A MEMORY DISORDERS CLINIC |
| Catherine Mummery | UK | BEYOND AMYLOID - THE NEXT STEPS IN TREATMENTS FOR ALZHEIMER'S DISEASE |
| Melissa Murray | USA | NEUROPATHOLOGIC LANDSCAPE OF BRAIN HEALTH |
| Henrietta Nielsen | Sweden | APOE PERIPHERAL SIGNATURES AND IMPLICATIONS TO NEURODEGENERATION |
| Laura Nisenbaum | USA | DRIVING INNOVATION IN ALZHEIMER’S TREATMENT: COMBINATION THERAPIES AND PRECISION MEDICINE |
| Agneta Nordberg | Sweden | TRACING ASTROCYTIC AND SYNAPTIC PROTEIN INTERACTIONS IN EARLY AD BY MULTIMODAL BRAIN IMAGING AND PLASMA BIOMARKERS |
| Tiago Outerio | Germany | UNDERSTANDING THE PATHOBIOLOGY OF ALPHA-SYNUCLEIN |
| Ronald Petersen | USA | PRECLINICAL ALZHEIMER'S DISEASE |
| Werner Poewe | Austria | TESTING FOR ALPHA-SYNUCLEIN SEEDING ACTIVITY IN HYPOSMIA |
| Marco Prado | Canada | CHOLINERGIC CONTROL OF CIRCUIT VULNERABILITY AND RESILIENCE IN ALZHEIMER’S DISEASE |
| Laura Ranum | USA | REPEAT ASSOCIATED NON-AUG PROTEINS AS THERAPEUTIC TARGETS AND GENE DISCOVERY TOOLS FOR ALS AND FTD |
| Stephen Salloway | USA | UPDATE ON SAFE USE OF AMYLOID-LOWERING ANTIBODIES |
| Philip Scheltens | Netherlands | ANTI TAU THERAPIES: WHERE DO WE STAND? |
| Suzanne Schindler | USA | REAL-WORLD USE OF BLOOD TESTS AND TREATMENTS FOR ALZHEIMER'S DISEASE |
| Michael Schlossmacher | Canada | HYPOSMIA OF PARKINSON'S: AN UPDATE FROM OLFACTION TESTING TO DIAGNOSTIC UTILITY TO NEUROPATHOLOGICAL STUDIES |
| Taylor Schmitz | Canada | THE PRICE OF PLASTICITY: CHOLINERGIC SYNAPTIC FUNCTION IN AGING AND DISEASE |
| Julia Schumacher | Germany | IN VIVO ASSESSMENT OF NEUROTRANSMITTER CHANGES IN LEWY BODY DISEASE |
| Menachem Segal | Israel | PROTECTING MPS NEURONS FROM NEUROTOXIC INSULTS |
| Dennis Selkoe | USA | SCREENING HUMAN NEURONAL CULTURE SYSTEM SCREENED WITH AD BRAIN DIFFUSIBLE OLIGOMERS IDENTIFIES B28, A MONOCLONAL THAT CLEARS PLAQUES, AND LOWERS OLIGOMERS IN APP NLGF KI MICE BY >90% WHILE PRESERVING NEURONS AND MEMORY. |
| Jie Shen | USA | APP AND PRESENILIN IN AD PATHOGENESIS |
| Tamara Shiner | Israel | GENETIC FACTORS IN DEMENTIA WITH LEWY BODIES |
| Sam Sisodia | USA | MECHANISMS UNDERLYING SPECIFIC MODULATION OF AMYLOIDOSIS BY PERTURBATIONS OF THE GUT MICROBIOME |
| Beka Solomon | Israel | TARGET-DIRECTED APP ANTIBODIES MITIGATE INTRANEURONAL ABETA ACCUMULATION IN NEURODEGENERATIVE DISEASES |
| Mona Soreq | Israel | PRE-PARKINSON'S DISEASE BLOOD TEST |
| Maria Grazia Spillantini | UK | GBA INHIBITION AND ALPHA-SYNUCLEIN |
| Peter St. George-Hyslop | Canada | MOLECULAR SIGNALLING PATHWAYS GOVERNING MICROGLIAL SENESCENCE IN NEURODEGENERATION |
| Fabrizio Stocchi | Italy | SYMPTOMATIC AND DISEASE MODIFYING THERAPY IN PARKINSON’S DISEASE |
| Malu Tansey | USA | THE ROLE OF IMMUNE AGING IN NEURODEGENERATION |
| Rudolph Tanzi | USA | RESILIENCE AND RESISTANCE TO ALZHEIMER’S DISEASE: FROM GENES TO THERAPEUTICS |
| Charlotte Teunissen | Netherlands | THE RISE OF QUANTITATIVE FLUID BIOMARKERS FOR LEWY BODY AND TDP-43 (CO-)PATHOLOGIES |
| Li-Huei Tsai | USA | THE ROLE OF NEUROIMMUNE INTERACTIONS IN NEURODEGENERATION |
| Robert Vassar | USA | EXPLORING THE MECHANISM LINKING ABETA AND TAU IN ALZHEIMER’S DISEASE |
| Rimona S Weil | UK | IMAGING BIOMARKERS IN LEWY BODY DEMENTIA |
| Michael Weiner | USA | TBA |
| Donna Wilcock | USA | THE CHALLENGES AND OPPORTUNITIES TO ADD "V" TO "ATN" |
| Manfred Windisch | Austria | PROOF OF CONCEPT CLINICAL PHASE 2 A TRIAL WITH THE SPECIFIC M1 AGONIST1 - |
| Tony Wyss-Coray | USA | MOLECULAR SIGNATURES OF BRAIN FUNCTION |
